- CEO
- Suwit Ngampuphan
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- Mueang Thailand
- IPO Date
- Jun 21, 2023
- Business
- Bangkok Lab and Cosmetic Public Company Limited manufactures, develops, and distributes generic pharmaceuticals, herbal medicines, cosmeceuticals, dietary supplements, and veterinary health products. The company operates through two core business segments: Proprietary Brand Manufacturing and Distribution, and Original Equipment and Design Manufacturing (OEM/ODM) Services. Its product portfolio comprises modern generic pharmaceuticals, including analgesics, anti-inflammatory agents, antibiotics, cardiovascular treatments, gastrointestinal drugs, respiratory therapies, antihistamines, dermatological medications, and central nervous system therapeutics; herbal medicinal products, such as standardized herbal extracts, capsule formulations, topical herbal preparations, and pain relief ointments derived from natural botanical ingredients under proprietary brands such as Kachana; cosmeceutical and dermatological skincare solutions, including anti-acne preparations, scar care gels, anti-aging serums, moisturizers, and dermatological cleansers marketed under brands such as Clenascar; nutritional and dietary supplements, featuring multivitamins, minerals, collagen formulations, and functional wellness products; and animal healthcare products, including veterinary pharmaceuticals, nutritional premixes, and antiparasitic solutions for livestock and companion animals. In addition to finished goods, the company provides comprehensive contract manufacturing, formulation development, regulatory registration, analytical testing, and packaging services for third-party commercial brand owners. Bangkok Lab and Cosmetic Public Company Limited serves public and private hospitals, medical clinics, commercial pharmacy chains, independent drugstores, modern trade retailers, and veterinary institutions across Thailand, while exporting products to international markets across Southeast Asia, including Cambodia, Laos, Myanmar, and Vietnam. Founded in 1993, the company is headquartered in Ratchaburi Province, Thailand, with executive and commercial operations based in Bangkok. In recent developments, the company completed its initial public offering and listed its ordinary shares on the Stock Exchange of Thailand under the ticker symbol BLC; invested in the construction and operational expansion of a new pharmaceutical manufacturing facility and research center in Ratchaburi to enhance production capacity in accordance with PIC/S GMP standards; established strategic distribution agreements to expand its commercial footprint across regional export markets; expanded its joint research initiatives with academic institutions to accelerate the commercialization of value-added herbal medicines; and introduced several new product extensions across its generic therapeutic, dermatological care, and preventative wellness lines.